Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapies for unmet medical needs in the US. They offer LUPKYNIS to treat adult lupus nephritis patients. They have a collaboration agreement with Otsuka Pharmaceutical Co., Ltd. Founded in 1993, Aurinia is headquartered in Edmonton, Canada.
| Indicator | Value |
|---|---|
| PER | 200.4 |
| EV/EBITDA | 20.9 |
| Price/Free Cash Flow' | 26.1 |
| ROIC | 9.7% |
| Net Debt/EBITDA | 100.0 |